• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Imaging Diagnostic Systems Features CT Laser Mammography Clinical Studies In Brazil

Posted on: Wednesday, 19 April 2006, 09:01 CDT

FORT LAUDERDALE, Fla., April 19 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc. (BULLETIN BOARD: IMDS) will display CT Laser Mammography (CTLM(R)) clinical cases from international Luminary Partner sites at the 36th annual meeting of the Sao Paulo Society of Radiology, April 20 - 23 in Sao Paulo, Brazil. The cases highlight the capability of CTLM to image angiogenesis, usually associated with breast cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )

IDSI has announced plans to commercialize the CTLM system throughout Central and South America; this exhibition marks the third major South American conference attended in less than ten months.

The annual meeting of the Sao Paulo Society of Radiology, Jornada Paulista de Radiologia (JPR) is one of the most important radiological meetings, featuring physician review courses, technical exhibits, symposia, and commercial exhibits. The meeting attracts prominent Brazilian and international radiologists.

IDSI will be located at booth #35 with Pyramid Medical Systems, one of Brazil's largest medical device distributors.

Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for its Computed Tomography Mammography (CTLM(R)) system to be used as an adjunct to mammography. The Company's PMA application will be submitted in its entirety at the completion of the data collection and review process. The FDA has determined that the Company's clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM(R) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Mammography system.

Please visit Imaging Diagnostic Systems' website at: http://www.imds.com/ for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filing with the Securities Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations: Rick Lutz 404-261-1196 lcgroup@mindspring.com

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.com

Imaging Diagnostic Systems, Inc.

CONTACT: Rick Lutz, +1-404-261-1196, or lcgroup@mindspring.com, forImaging Diagnostic Systems

Web site: http://www.imds.com/

Source: PRNewswire-FirstCall

More News in this Category